CLINICAL TRIAL OF RECOMBINANT YEAST GM-CSF AS MODULATOR OF MONOCYTE/MACROPHAGE

这项研究将评估GM-CSF在一定剂量范围内对人类的影响 单核/巨噬细胞活化，以单核/巨噬细胞衡量 细胞毒性，单核细胞肿瘤坏死因子释放，干扰素-γ诱导，单核细胞 IL-1诱导，单核细胞肿瘤坏死因子释放，干扰素-γ诱导，单核细胞 IL-1诱导、单核细胞DR和Fc表达及干扰素β2基因表达 单核/巨噬细胞和淋巴细胞表型的诱导。它还将 测定肿瘤患者应用GM-CSF的毒性。 格兰特M01RR000960286 本研究的目的是确定小鼠的存活率和死亡率。 胶质母细胞瘤患者的无瘤存活率 治疗剂量为1.20Gyb.i.d的六个总剂量水平之一； 确定正常组织对1.20Gy超分割的耐受性 B.i.d。在同一天给药间隔4-8小时，按总剂量计 64.80Gy54次/次、72.00Gy60Fx次、76.80Gy60Fx次。

This study will evaluate the effects of GM-CSF over a dose range on human monocyte/macrophage activation, as measured by monocyte/macrophage cytotoxicity, monocyte TNF release, interferon-gamma induction, monocyte IL-1 induction, monocyte TNF release, interferon-gamma induction, monocyte IL-1 induction, monocyte DR and Fc expression, and interferonbeta2 mRNA induction in monocytes/macrophages and lymphocyte phenotypes. It will also determine the toxicity of GM-CSF administered to patients with cancer. GRANT M01RR000960286 The objects of this study are to determine the survival rate and the disease-free survival rate for patients with glioblastomamultiforsme treated to one of six total dose levels delivered at 1.20Gy b.i.d; to determine normal tissue tolerance to hyperfraction delivered at 1.20 Gy b.i.d. with 4-8 h between fractions delivered the same day, to total doses of 64.80 Gy/54 Fx, 72.00 Gy/60 Fx, and 76.80 Gy/64 Fx.